Fig. 1From: Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastasesTreatment overview. Biomarker-matched targeted therapy was mainly based on molecular analysis of CSF. Osimer, osimertinib; CSF, cerebrospinal fluid; chemo, chemotherapy; bevac, bevacizumabBack to article page